What's Happening?
Researchers at the University of Calgary are investigating the potential of vitamin B3, also known as niacin, to improve treatment outcomes for glioblastoma, a highly aggressive form of brain cancer. The study, led by Dr. Gloria Roldan Urgoiti and Dr. Wee
Yong, involves adding high doses of niacin to standard treatments like surgery, radiation, and chemotherapy. Initial laboratory experiments in mice showed promising results, leading to a Phase I and II clinical trial involving human participants. The trial aims to determine if niacin can rejuvenate immune cells to better attack tumor cells. Early results from 24 patients indicate a 28% improvement in progression-free survival at six months compared to historical data.
Why It's Important?
Glioblastoma is one of the most challenging brain cancers to treat, with survival rates remaining largely unchanged for decades. The potential use of vitamin B3 to enhance immune response could represent a significant advancement in treatment options. If successful, this approach could improve survival rates and quality of life for patients. The study also highlights the importance of exploring new therapeutic avenues in oncology, particularly those that leverage the body's immune system. However, researchers caution that high doses of vitamins can have adverse effects, underscoring the need for careful medical supervision.
What's Next?
The research team plans to complete the final analysis once the trial reaches 48 participants, expected by late 2026 or early 2027. Continued monitoring and follow-up scans will be crucial for assessing the long-term efficacy and safety of niacin as a treatment adjunct. The study's outcomes could influence future clinical practices and guidelines for glioblastoma treatment, potentially leading to broader clinical trials and eventual integration into standard care protocols.
